By Chris Wack 



  Eli Lilly & Co. said Thursday that it and Boehringer Ingelheim saw positive top-line results from a phase 3 trial in adults with heart failure with reduced ejection fraction, with and without diabetes. 


  The companies said the trial met its primary endpoint, demonstrating superiority with Jardiance empagliflozin 10 mg compared with placebo in reducing the risk for the composite of cardiovascular death or hospitalization due to heart failure, when added to standard of care. Overall, the safety profile was similar to the known safety profile of Jardiance. 


   Lilly said a second trial is exploring the effect of Jardiance on cardiovascular death or hospitalization in adults with heart failure with preserved ejection fraction, and results are expected in 2021. 


  Write to Chris Wack at chris.wack@wsj.com